Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
ALDX on Nasdaq
Shares outstanding
60,026,563
Price per share
$5.18
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
39,235,813
Total reported value
$204,754,193
% of total 13F portfolios
0%
Share change
+4,998,459
Value change
+$26,942,517
Number of holders
130
Price from insider filings
$5.18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 8.7% +27% $27,260,463 +$6,110,950 5,222,311 +29% Perceptive Advisors LLC 30 Sep 2025

As of 30 Sep 2025, 130 institutional investors reported holding 39,235,813 shares of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX). This represents 65% of the company’s total 60,026,563 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Knoll Capital Management, LLC 9.1% 5,475,516 0% 15% $28,582,193
PERCEPTIVE ADVISORS LLC 8.7% 5,222,311 +29% 0.8% $27,260,463
BlackRock, Inc. 6.3% 3,804,920 -1.2% 0% $19,861,683
VANGUARD GROUP INC 6% 3,591,869 +2.6% 0% $18,749,556
ARDSLEY ADVISORY PARTNERS LP 3.2% 1,900,000 -7.3% 1.5% $9,918,000
AQR CAPITAL MANAGEMENT LLC 2.5% 1,505,360 +2.1% 0.01% $7,857,980
D. E. Shaw & Co., Inc. 2.3% 1,379,843 +183% 0.01% $7,202,780
KINGDON CAPITAL MANAGEMENT, L.L.C. 2.2% 1,331,791 0% 1.1% $6,951,949
GEODE CAPITAL MANAGEMENT, LLC 2% 1,176,420 +2.6% 0% $6,142,220
KENNEDY CAPITAL MANAGEMENT LLC 1.9% 1,112,213 +62% 0.13% $5,805,752
STATE STREET CORP 1.8% 1,102,674 +4.4% 0% $5,755,958
MORGAN STANLEY 1.8% 1,083,319 +40% 0% $5,654,926
JACOBS LEVY EQUITY MANAGEMENT, INC 1.6% 947,551 +49% 0.02% $4,946,216
ACADIAN ASSET MANAGEMENT LLC 1.4% 835,811 +334% 0.01% $4,360,000
683 Capital Management, LLC 1.4% 820,000 -24% 0.39% $4,280,400
DIMENSIONAL FUND ADVISORS LP 1.1% 648,371 -9.8% 0% $3,384,462
NORTHERN TRUST CORP 0.68% 407,960 +0.99% 0% $2,129,551
BANK OF AMERICA CORP /DE/ 0.65% 390,078 +591% 0% $2,036,207
WELLS FARGO & COMPANY/MN 0.6% 361,469 -0.74% 0% $1,886,868
DEUTSCHE BANK AG\ 0.52% 314,728 +2.6% 0% $1,642,880
TWO SIGMA INVESTMENTS, LP 0.45% 273,054 +390% 0% $1,425,342
WOODSTOCK CORP 0.44% 266,756 0% 0.12% $1,392,466
JANE STREET GROUP, LLC 0.42% 251,518 +160% 0% $1,312,924
Palo Alto Investors LP 0.38% 225,465 0% 0.22% $1,176,927
UBS Group AG 0.33% 200,739 +87% 0% $1,047,857

Institutional Holders of Aldeyra Therapeutics, Inc. - Common Stock, par value $0.001 per share (ALDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 355,159 $1,802,959 +$134,881 $5.18 10
2025 Q3 39,235,813 $204,754,193 +$26,942,517 $5.22 130
2025 Q2 34,234,495 $131,165,420 -$14,803,188 $3.83 121
2025 Q1 37,522,553 $215,581,473 +$3,357,658 $5.75 124
2024 Q4 37,181,880 $185,566,828 +$2,534,928 $4.99 117
2024 Q3 36,411,204 $196,356,138 +$6,361,987 $5.39 112
2024 Q2 35,332,656 $116,900,281 +$1,499,751 $3.31 103
2024 Q1 21,890,285 $71,586,711 -$640,366 $3.27 53
2023 Q4 31,285 $109,810 +$41,948 $3.51 2
2023 Q3 37,770,545 $252,278,431 -$9,932,620 $6.68 119
2023 Q2 39,026,743 $327,422,641 +$24,743,864 $8.39 118
2023 Q1 35,574,807 $353,239,423 +$15,483,343 $9.93 106
2022 Q4 34,161,761 $237,764,382 -$18,891,662 $6.96 92
2022 Q3 36,842,606 $196,739,099 +$1,911,655 $5.34 81
2022 Q2 36,232,884 $144,572,768 -$7,664,822 $3.99 84
2022 Q1 38,538,559 $171,372,242 +$11,502,033 $4.44 99
2021 Q4 36,088,033 $144,393,076 -$45,185,947 $4.00 107
2021 Q3 39,730,740 $348,833,599 -$59,103,235 $8.78 114
2021 Q2 45,248,543 $512,677,641 +$153,597,146 $11.33 129
2021 Q1 31,652,997 $375,902,916 +$119,466,309 $11.88 105
2020 Q4 19,865,806 $136,271,026 -$9,942,547 $6.86 90
2020 Q3 23,795,415 $176,216,891 +$71,113,440 $7.41 83
2020 Q2 14,638,872 $61,039,721 -$6,618,577 $4.17 76
2020 Q1 16,769,610 $41,415,535 -$6,411,750 $2.47 69
2019 Q4 17,661,481 $102,610,148 +$1,346,607 $5.81 74
2019 Q3 15,495,919 $81,677,097 +$645,163 $5.27 66
2019 Q2 16,884,404 $101,304,468 +$1,180,143 $6.00 73
2019 Q1 16,355,463 $147,693,642 -$5,568,403 $9.03 76
2018 Q4 17,145,776 $141,380,000 -$14,233,716 $8.30 73
2018 Q3 18,024,524 $246,973,570 +$80,293,823 $13.80 86
2018 Q2 12,131,183 $96,444,142 +$14,632,797 $7.95 65
2018 Q1 10,285,108 $77,137,000 +$3,819,595 $7.50 41
2017 Q4 9,759,606 $66,364,000 +$4,217,362 $6.80 34
2017 Q3 9,211,834 $65,820,504 +$12,713,793 $7.20 34
2017 Q2 7,437,286 $34,736,000 -$2,554,115 $4.65 24
2017 Q1 7,897,813 $37,958,000 +$8,366,791 $5.00 24
2016 Q4 6,136,618 $32,831,000 +$111,606 $5.35 20
2016 Q3 6,112,780 $47,882,100 -$1,306,681 $7.82 22
2016 Q2 6,355,443 $36,160,450 +$11,375,445 $5.69 24
2016 Q1 4,369,078 $18,302,243 -$216,100 $4.19 25
2015 Q4 4,427,755 $30,018,000 +$376,497 $6.78 20
2015 Q3 4,330,050 $25,241,000 +$601,395 $5.83 22
2015 Q2 4,214,406 $32,767,000 +$19,548,416 $7.76 22
2015 Q1 1,691,795 $17,415,000 +$8,386,372 $10.18 15
2014 Q4 870,129 $6,277,000 +$82,000 $7.18 5
2014 Q3 859,068 $5,161,000 +$34,237 $5.49 5
2014 Q2 852,047 $5,639,000 +$5,638,031 $6.56 5